Information Provided By:
Fly News Breaks for February 25, 2019
IMMU
Feb 25, 2019 | 20:18 EDT
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating an $20 price target on Immunomedics after its Q4 results and pipeline update. The analyst says the company offered "minimal updates for its timeline around a potential BLA re-submission" as it continues to work on finalizing the response strategy, but believes that today's announcement of the resignation of its CEO should not impact the timing of the response.
News For IMMU From the Last 2 Days
There are no results for your query IMMU